2. Search Result
Search Result
Results for "

GPR109A

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

2

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-107579
    Acifran

    AY 25712

    		 GPR109A Cardiovascular Disease
    Acifran (AY 25712), an antihyperlipidemic agent, is an orally active agonist of GPR109A (HM74A) and GPR109B, the high and low affinity receptors for Niacin .
    Acifran
  • HY-119222
    GSK256073
    2 Publications Verification

    		 GPR109A Metabolic Disease
    GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia . GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
    GSK256073
  • HY-10680
    MK-6892
    5 Publications Verification

    		 GPR109A Cancer
    MK-6892 is a potent, selective, and full agonist for the high affinity nicotinic acid (NA) receptor GPR109A. Ki and GTPγS EC50 of MK-6892 on the Human GPR109A is 4 nM and 16 nM, respectively.
    MK-6892
  • HY-17585
    Mepenzolate bromide
    3 Publications Verification

    		 mAChR GPR109A Others Inflammation/Immunology
    Mepenzolate bromide is an orally administered muscarinic receptor antagonist with Kis of 0.68 and 2.6 nM for hM2R and hM3R, respectively. Mepenzolate bromide can be used to suppress the gastrointestinal hypermotility associated with irritable bowel syndrome .Mepenzolate bromide is a GPR109A inhibitor .
    Mepenzolate bromide
  • HY-107581
    MK-1903

    		GPR109A Metabolic Disease
    MK-1903 is a potent and selective hydroxycarboxylic acid receptor 2 (HCA2, GPR109A) full agonist .
    MK-1903
  • HY-W095200
    GPR109 receptor agonist-2

    		GPR109A Cardiovascular Disease
    GPR109 receptor agonist-2 (Compound 5) is a selective GPR109a agonist with a pEC50 of 5.53 .
    GPR109 receptor agonist-2
  • HY-103252
    Monomethyl fumarate
    5 Publications Verification

    		 GPR109A Drug Metabolite Neurological Disease Inflammation/Immunology
    Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease .
    Monomethyl fumarate
  • HY-13008
    MK-0354
    1 Publications Verification

    		 GPR109A Cardiovascular Disease
    MK-0354 is a partial agonist of GPR109a receptor, for hGPR109a/ mGPR109a with EC50 of 1.65/1.08 μM, showed no activation of GPR109b.
    MK-0354
  • HY-119222A
    GSK256073 tris

    		GPR109A Metabolic Disease
    GSK256073 tris is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 tris acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia . GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
    GSK256073 tris
  • HY-103252S1
    Monomethyl fumarate-d5

    		Isotope-Labeled Compounds GPR109A Drug Metabolite Neurological Disease Inflammation/Immunology
    Monomethyl fumarate-d5 is deuterium labeled Monomethyl fumarate. Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease[1][2][3].
    Monomethyl fumarate-d5
  • HY-111143
    SCH-900271

    		nAChR Metabolic Disease
    SCH-900271 is an orally active, potent nicotinic acid receptor (NAR) agonist with an EC50 of 2 nM in the hu-GPR109a assay. SCH-900271 exhibits dose-dependent inhibition of plasma free fatty acid (FFA). SCH-900271 has an improved therapeutic window to flushing .
    SCH-900271
  • HY-135982
    GPR81 agonist 1
    2 Publications Verification

    		 Hydroxycarboxylic Acid Receptor (HCAR) Metabolic Disease
    GPR81 agonist 1 is a potent and highly selective GPR81 agonist, with EC50s of 58 nM and 50 nM for human and mouse GPR81, respectively. GPR81 agonist 1 inhibits lipolysis in differentiated 3T3-L1 adipocytes. GPR81 agonist 1 suppresses lipolysis in mice without cutaneous flushing. GPR81 agonist 1 displays remarkable selectivity for GPR81 over GPR109a .
    GPR81 agonist 1
  • HY-107579R
    Acifran (Standard)

    		GPR109A Cardiovascular Disease
    (2S,5R,6R)-Ticarcillin (disodium) (Standard) is the analytical standard of (2S,5R,6R)-Ticarcillin (disodium). This product is intended for research and analytical applications. (2S,5R,6R)-Ticarcillin disodium is an injectable antibiotic for the treatment of Gram-negative bacteria, particularly Pseudomonas aeruginosa. It is also one of the few antibiotics capable of treating Stenotrophomonas maltophilia infections.
    Acifran (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: